Sébastien Denanglaire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sébastien Denanglaire has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Abdulkader Azouz
Universite Libre de Bruxelles
20 shared publications - Coralie Henin
Laboratoire d’Immunobiologie, Université Libre de Bruxelles (ULB), Gosselies, Belgium
20 shared publications - Muriel Moser
Laboratoire d’Immunobiologie, Université Libre de Bruxelles (ULB), Gosselies, Belgium
20 shared publications - Oberdan Leo
U-CRI (ULB Center for Research in Immunology), Université Libre de Bruxelles (ULB)
20 shared publications - Stanislas Goriely
Universite Libre de Bruxelles
20 shared publications - Benoit J. Van Den Eynde
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
14 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (5) , 1625-1647
Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma
Tumor-associated neutrophils (TANs) represent a large fraction of immune cells in tumors, but how their regulation and function vary in distinct cancer subtypes remains unknown. In Kras LSL-G12D/WT ; p53 fl/fl mouse models of lung adenocarcinoma (LUAD), TANs have an increased lifespan compared to normal neutrophils. Specifically, TANs upregulate the anti-apoptotic protein Bcl-xL, whose blockade by a BH3 mimetic selectively kills ageing TANs and diminishes tumor growth. Here, we have addressed this issue in lung squamous cell carcinoma (LUSC) using the Rosa26 LSL-Sox2-IRES-GFP ; Nkx2-1 fl/fl ; Lkb1 fl/fl mouse model, where we demonstrate increased TAN survival with a rise in Bcl-xL similarly to LUAD. However, unlike in LUAD, inhibiting Bcl-xL alone was insufficient to alter tumor progression in LUSC. After carboplatin and paclitaxel treatment, a combination chemotherapy used in human LUSC, we detected increased neutrophils in circulation, spleen and tumors, and increased Bcl-xL in neutrophils and TANs. Bcl-xL blockade decreased the pool of Bcl-xL-high TANs and synergized with chemotherapy. Altogether, our results suggest distinct outcomes for targeting TANs in different tumor types and reinforce the concept of repurposing BH3 mimetics against cancer.
- 31 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (5) , 1625-1647
Open AccessBcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma
Tumor-associated neutrophils (TANs) represent a large fraction of immune cells in tumors, but how their regulation and function vary in distinct cancer subtypes remains unknown. In Kras LSL-G12D/WT ; p53 fl/fl mouse models of lung adenocarcinoma (LUAD), TANs have an increased lifespan compared to normal neutrophils. Specifically, TANs upregulate the anti-apoptotic protein Bcl-xL, whose blockade by a BH3 mimetic selectively kills ageing TANs and diminishes tumor growth. Here, we have addressed this issue in lung squamous cell carcinoma (LUSC) using the Rosa26 LSL-Sox2-IRES-GFP ; Nkx2-1 fl/fl ; Lkb1 fl/fl mouse model, where we demonstrate increased TAN survival with a rise in Bcl-xL similarly to LUAD. However, unlike in LUAD, inhibiting Bcl-xL alone was insufficient to alter tumor progression in LUSC. After carboplatin and paclitaxel treatment, a combination chemotherapy used in human LUSC, we detected increased neutrophils in circulation, spleen and tumors, and increased Bcl-xL in neutrophils and TANs. Bcl-xL blockade decreased the pool of Bcl-xL-high TANs and synergized with chemotherapy. Altogether, our results suggest distinct outcomes for targeting TANs in different tumor types and reinforce the concept of repurposing BH3 mimetics against cancer.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Identification of predominant IFNγ-producing cell population and their functional characterization
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Identification of predominant IFNγ-producing cell population and their functional characterization
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is associated with subsets exhibiting elevated expression of MHC II
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is associated with subsets exhibiting elevated expression of MHC II
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Although immune checkpoint inhibitors have led to durable responses in various cancer types, a substantial proportion of patients do not respond to these interventions. To uncover potential factors associated with a positive response to immunotherapy, we used a bilateral tumor model with P815 mastocytoma implanted in DBA/2 mice. In this model, only a fraction of tumor-bearing mice responds to anti–PD-1 treatment. Thus, it provides a valuable model to explore the influence of the tumor microenvironment (TME) in determining the efficacy of immune checkpoint blockade–based immunotherapies. It also allows for the analysis of a pretreatment tumor and inference of its treatment outcome based on the response observed in the contralateral tumor. In this study, we report that tumor-reactive CD8+ T-cell clones expressing high levels of Tim-3 are associated with a positive antitumor response following anti–PD-1 administration. Our study also revealed distinct differentiation dynamics in tumor-infiltrating myeloid cells in responding and nonresponding mice. An IFNγ-enriched TME promoted the differentiation of monocytes into PD-L1posMHCIIhigh cells in mice responding to immunotherapy. Monocytes present in the TME of nonresponding mice failed to reach the same final stage of differentiation trajectory, suggesting that an altered monocyte-to-macrophage differentiation route may hamper the response to immune checkpoint blockade. These insights will direct future research toward a temporal analysis of tumor-associated macrophages, aiming to identify factors responsible for transitions between differentiation states within the TME. This approach may pave the way for novel strategies to enhance the efficacy of PD-1 blockade.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Although immune checkpoint inhibitors have led to durable responses in various cancer types, a substantial proportion of patients do not respond to these interventions. To uncover potential factors associated with a positive response to immunotherapy, we used a bilateral tumor model with P815 mastocytoma implanted in DBA/2 mice. In this model, only a fraction of tumor-bearing mice responds to anti–PD-1 treatment. Thus, it provides a valuable model to explore the influence of the tumor microenvironment (TME) in determining the efficacy of immune checkpoint blockade–based immunotherapies. It also allows for the analysis of a pretreatment tumor and inference of its treatment outcome based on the response observed in the contralateral tumor. In this study, we report that tumor-reactive CD8+ T-cell clones expressing high levels of Tim-3 are associated with a positive antitumor response following anti–PD-1 administration. Our study also revealed distinct differentiation dynamics in tumor-infiltrating myeloid cells in responding and nonresponding mice. An IFNγ-enriched TME promoted the differentiation of monocytes into PD-L1posMHCIIhigh cells in mice responding to immunotherapy. Monocytes present in the TME of nonresponding mice failed to reach the same final stage of differentiation trajectory, suggesting that an altered monocyte-to-macrophage differentiation route may hamper the response to immune checkpoint blockade. These insights will direct future research toward a temporal analysis of tumor-associated macrophages, aiming to identify factors responsible for transitions between differentiation states within the TME. This approach may pave the way for novel strategies to enhance the efficacy of PD-1 blockade.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Effect of blocking IFNγ is particularly pronounced within myeloid cell populations
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Effect of blocking IFNγ is particularly pronounced within myeloid cell populations
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Flow cytometry gating strategy to analyze the influence of tumor-infiltrating immune cells on the response to immunotherapy
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Flow cytometry gating strategy to analyze the influence of tumor-infiltrating immune cells on the response to immunotherapy
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
P1A-specific CD8+ T cell infiltration is not sufficient alone for a successful tumor response
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
P1A-specific CD8+ T cell infiltration is not sufficient alone for a successful tumor response
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is linked to the M_3 scRNA-seq cluster
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is linked to the M_3 scRNA-seq cluster
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Comparative analysis of myeloid immune infiltrate composition in bilateral tumors
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Comparative analysis of myeloid immune infiltrate composition in bilateral tumors
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Response to anti-PD-1 treatment is a property of individual mice
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Response to anti-PD-1 treatment is a property of individual mice